Mar 20 |
Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results
|
Mar 18 |
Tango Therapeutics GAAP EPS of -$0.32 misses by $0.04, revenue of $5.43M misses by $2.81M
|
Mar 18 |
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
|
Mar 6 |
Tango Therapeutics to Participate in Upcoming Investor Conferences
|
Mar 5 |
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
Mar 3 |
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
|
Jan 31 |
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
|
Jan 25 |
Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs
|
Jan 7 |
Tango Therapeutics Must Produce Its Own Data To Justify Its Valuation
|
Jan 5 |
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|